Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study

Table 6

Clinically relevant differences between health states.

Health state comparisons	EQ-5D (mean utility)		QLQ-C30 (mean global QoL)
	Difference	Clinically relevant difference^1	Difference	Clinically relevant difference^2
1st-line CT (HS 1) versus 2nd-line CT (HS 2)	0.08	Positive	7.46	Little change
1st-line CT (HS 1) versus 3rd-line CT (HS 3)	−0.05	None	7.84	Little change
2nd-line CT (HS 2) versus 3rd-line CT (HS 3)	−0.14	Negative	0.38	No change
Progressive disease (HS 4) versus Off CT, preprogression (HS 5)	−0.21	Negative	−30.26	Very much change

Note: ¹0.074 difference in mean utility, ²“little change” (5–10 points change in the score), a “moderate change” (10–20 points), and “very much change” (>20 points).